Double heterozygosity for TP53 and BRCA1 mutations: clinical implications in populations with founder mutations.

This family highlights the need to genotype both parents, especially in populations with founder mutations, when a BRCA1 mutation is detected in an offspring, regardless of family history. The combination of mutations in these two genes presents a challenge for PGD since both genes are located on chromosome 17.